Calithera Biosciences, Inc.
CALADelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496671
Calithera Biosciences, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on May 26, 2023; 29 institutions reported holding it in 13F filings for Q2 2022, worth $4.44M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:19 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 31, 2022 | Jan 4, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Revenue | – | $9.75M | – | – | $22.3M |
| Operating expenses | $42.1M | $125.2M | $91.4M | $92.9M | $79.5M |
| Research and development | $28.5M | $53.5M | $71.0M | $76.3M | $66.2M |
| Selling, general and administrative | $13.5M | $20.9M | $20.4M | $16.6M | $13.3M |
| Operating income | -$42.1M | -$115.4M | -$91.4M | -$92.9M | -$57.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.6M | -$115.1M | -$90.1M | -$89.9M | -$54.6M |
| EPS, basic | $-4.60 | – | – | – | – |
| EPS, diluted | $-7.94 | – | – | – | – |
| Weighted shares, basic | 4.63M | – | – | – | – |
| Weighted shares, diluted | 4.99M | – | – | – | – |
| Margins and growth | |||||
| Operating margin | – | -1183.9% | – | – | -257.4% |
| Net margin | – | -1180.4% | – | – | -245.5% |
| Revenue growth, year over year | – | – | – | – | −14.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021! | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 31, 2022 | Jan 4, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Cash and equivalents | $25.5M | $59.5M | $107.1M | $60.4M | $51.1M |
| Short-term investments | – | – | $8.01M | $96.9M | $85.1M |
| Accounts receivable | – | – | $1.54M | $482.0K | $2.00M |
| Total current assets | $26.6M | $61.5M | $118.7M | $159.8M | $140.3M |
| Property, plant and equipment | $434.0K | $556.0K | $690.0K | $992.0K | $1.46M |
| Total assets | $28.7M | $64.8M | $125.6M | $168.8M | $142.7M |
| Accounts payable | $732.0K | $3.65M | $1.99M | $2.05M | $1.25M |
| Total current liabilities | $7.39M | $14.0M | $18.4M | $19.6M | $14.9M |
| Total liabilities | $8.28M | $15.7M | $23.2M | $26.3M | $16.0M |
| Shareholders' equity | $20.4M | $8.38M | $102.4M | $142.4M | $126.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 31, 2022 | Jan 4, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Operating cash flow | -$43.6M | -$66.3M | -$84.3M | -$78.7M | -$64.8M |
| Capital expenditures | $133.0K | $147.0K | $61.0K | $7.00K | $214.0K |
| Free cash flow | -$43.7M | -$66.4M | -$84.4M | -$78.8M | -$65.1M |
| Depreciation and amortization | $300.0K | $300.0K | $364.0K | $479.0K | $505.0K |
| Stock-based compensation | $4.03M | $10.3M | $8.06M | $6.47M | $7.44M |
| Investing cash flow | -$133.0K | $7.85M | $89.0M | -$10.8M | $52.8M |
| Financing cash flow | $9.65M | $10.7M | $42.1M | $98.9M | $14.6M |
| Net change in cash | -$34.1M | -$47.8M | $46.7M | $9.38M | $2.58M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 105.3% | – | – | 33.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Mar 24, 2023 | 4.87M | −93.8% | SEC |
| Nov 9, 2022 | 4.87M | −93.5% | SEC |
| Aug 11, 2022 | 4.87M | −93.4% | SEC |
| May 6, 2022 | 97.2M | +31.3% | SEC |
| Mar 25, 2022 | 78.7M | +7.4% | SEC |
| Nov 4, 2021 | 74.9M | +6.2% | SEC |
| Aug 3, 2021 | 74.1M | +5.0% | SEC |
| May 3, 2021 | 74.0M | +5.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2017, from 13F share counts: 1-for-20 in Q2 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.